1
|
Lasa-Saracíbar B, El Moukhtari SH, Tsotakos T, Xanthopoulos S, Loudos G, Bouziotis P, Blanco-Prieto MJ. In vivo biodistribution of edelfosine-loaded lipid nanoparticles radiolabeled with Technetium-99m: comparison of administration routes in mice. Eur J Pharm Biopharm 2022; 175:1-6. [DOI: 10.1016/j.ejpb.2022.04.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 04/08/2022] [Accepted: 04/19/2022] [Indexed: 02/07/2023]
|
2
|
Varlamova EA, Isagulieva AK, Morozova NG, Shmendel EV, Maslov MA, Shtil AA. Non-Phosphorus Lipids As New Antitumor Drug Prototypes. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2021. [DOI: 10.1134/s1068162021050356] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
3
|
Saraiva SM, Gutiérrez-Lovera C, Martínez-Val J, Lores S, Bouzo BL, Díez-Villares S, Alijas S, Pensado-López A, Vázquez-Ríos AJ, Sánchez L, de la Fuente M. Edelfosine nanoemulsions inhibit tumor growth of triple negative breast cancer in zebrafish xenograft model. Sci Rep 2021; 11:9873. [PMID: 33972572 PMCID: PMC8110995 DOI: 10.1038/s41598-021-87968-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 03/29/2021] [Indexed: 12/18/2022] Open
Abstract
Triple negative breast cancer (TNBC) is known for being very aggressive, heterogeneous and highly metastatic. The standard of care treatment is still chemotherapy, with adjacent toxicity and low efficacy, highlighting the need for alternative and more effective therapeutic strategies. Edelfosine, an alkyl-lysophospholipid, has proved to be a promising therapy for several cancer types, upon delivery in lipid nanoparticles. Therefore, the objective of this work was to explore the potential of edelfosine for the treatment of TNBC. Edelfosine nanoemulsions (ET-NEs) composed by edelfosine, Miglyol 812 and phosphatidylcholine as excipients, due to their good safety profile, presented an average size of about 120 nm and a neutral zeta potential, and were stable in biorelevant media. The ability of ET-NEs to interrupt tumor growth in TNBC was demonstrated both in vitro, using a highly aggressive and invasive TNBC cell line, and in vivo, using zebrafish embryos. Importantly, ET-NEs were able to penetrate through the skin barrier of MDA-MB 231 xenografted zebrafish embryos, into the yolk sac, leading to an effective decrease of highly aggressive and invasive tumoral cells' proliferation. Altogether the results demonstrate the potential of ET-NEs for the development of new therapeutic approaches for TNBC.
Collapse
Affiliation(s)
- Sofia M Saraiva
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
- Cancer Network Research (CIBERONC), Madrid, Spain
| | - Carlha Gutiérrez-Lovera
- Department of Zoology, Genetics and Physical Anthropology, Campus of Lugo, University of Santiago de Compostela, Lugo, Spain
| | - Jeannette Martínez-Val
- Department of Zoology, Genetics and Physical Anthropology, Campus of Lugo, University of Santiago de Compostela, Lugo, Spain
| | - Sainza Lores
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
| | - Belén L Bouzo
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
| | - Sandra Díez-Villares
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
- Cancer Network Research (CIBERONC), Madrid, Spain
| | - Sandra Alijas
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
| | - Alba Pensado-López
- Department of Zoology, Genetics and Physical Anthropology, Campus of Lugo, University of Santiago de Compostela, Lugo, Spain
- Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), University of Santiago de Compostela, Santiago de Compostela, Spain
| | - Abi Judit Vázquez-Ríos
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
- Cancer Network Research (CIBERONC), Madrid, Spain
| | - Laura Sánchez
- Department of Zoology, Genetics and Physical Anthropology, Campus of Lugo, University of Santiago de Compostela, Lugo, Spain
| | - María de la Fuente
- Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain.
- Cancer Network Research (CIBERONC), Madrid, Spain.
| |
Collapse
|
4
|
Yadav P, Mishra H, Nagpal M, Aggarwal G. Expanding Opportunities in Treatment of Leukemia by Solid Lipid Nanoparticles. LETT DRUG DES DISCOV 2021. [DOI: 10.2174/1570180817999201001155508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Leukemia is a severe type of blood cancer that involves an abnormal proliferation
of blood-forming cells. Its conventional treatment faces many challenges, including resistance,
lack of specificity and high unwanted toxicity of drugs. Nano drug delivery systems help in
overcoming these challenges by delivering the drug to the target site actively or passively. Solid
lipid nanoparticles are gaining popularity because they reduce unwanted toxicity, are biocompatible,
increase bioavailability and are versatile in terms of incorporated agents (hydrophilic as well as
lipophilic drugs, genes, enzymes, etc.).
Purpose:
The aim of this review is to discuss recent advancements in anti-leukemic therapy utilizing
solid lipid nanoparticles (SLNs) as successful carriers in enhancing the efficiency of the treatment
and bioavailability of the incorporated drug along with overcoming multidrug resistance.
Methods:
This review represents the existing literature on the applications of SLNs in anti-leukemic
therapy. A qualitative literature review has been performed for this purpose. We performed keyword
research in popular databases such as Google Scholar, Wiley, Elsevier, Scopus, Google patent
and PubMed. Only articles published in English and from reputed journals from specific fields were
considered. Benchmark studies having major importance from 2000 to 2020 were selected to follow
the progress in the field across the globe.
Results:
This article improves the understanding of the role of SLNs in the treatment of leukemia.
Traditional anti-leukemic therapy involves many challenges, including resistance, lack of specificity
and high unwanted toxicity of drugs. SLNs are emerging as a better alternative to conventional
delivery systems as they can reduce unwanted toxicity, are biocompatible, and can provide active as
well as passive molecular targeting.
Conclusion:
SLNs provide several advantages in drug delivery for leukemia, including enhancement
of efficiency and bioavailability and reduction of toxicity by virtue of their small size, lipid
core, non-dependency on organic solvents and versatility in terms of incorporated drugs.
Collapse
Affiliation(s)
- Prarthna Yadav
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi,India
| | - Harshita Mishra
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi,India
| | - Manju Nagpal
- Chitkara College of Pharmacy, Chitkara University, Punjab,India
| | - Geeta Aggarwal
- School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi,India
| |
Collapse
|
5
|
Garbayo E, Pascual‐Gil S, Rodríguez‐Nogales C, Saludas L, Estella‐Hermoso de Mendoza A, Blanco‐Prieto MJ. Nanomedicine and drug delivery systems in cancer and regenerative medicine. WILEY INTERDISCIPLINARY REVIEWS-NANOMEDICINE AND NANOBIOTECHNOLOGY 2020; 12:e1637. [DOI: 10.1002/wnan.1637] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Revised: 03/01/2020] [Accepted: 03/27/2020] [Indexed: 12/18/2022]
Affiliation(s)
- Elisa Garbayo
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition University of Navarra Pamplona Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA) Pamplona Spain
| | - Simon Pascual‐Gil
- Toronto General Hospital Research Institute, University Health Network Toronto Ontario Canada
- Institute of Biomaterials and Biomedical Engineering University of Toronto Toronto Ontario Canada
| | - Carlos Rodríguez‐Nogales
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition University of Navarra Pamplona Spain
| | - Laura Saludas
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition University of Navarra Pamplona Spain
| | | | - Maria J. Blanco‐Prieto
- Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition University of Navarra Pamplona Spain
- Instituto de Investigación Sanitaria de Navarra (IdiSNA) Pamplona Spain
| |
Collapse
|
6
|
Sun Y, Sun ZL. Transferrin-conjugated polymeric nanomedicine to enhance the anticancer efficacy of edelfosine in acute myeloid leukemia. Biomed Pharmacother 2016; 83:51-57. [PMID: 27470549 DOI: 10.1016/j.biopha.2016.05.046] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2016] [Revised: 05/28/2016] [Accepted: 05/29/2016] [Indexed: 11/26/2022] Open
Abstract
In this study, transferrin (Tf)-conjugated polyethylene glycol (PEG)-poly-l-lysine (PLL)-poly(lactic-co-glycolic acid) (PLGA) (PEG-PLL-PLGA)-based micellar formulations were successfully prepared for the delivery of edelfosine (EDS) in leukemia treatment. The micelles were nanosized and presented spherical shaped particles. Our in vitro data suggest that the nanoformulations maintain the biological activity of drugs for longer periods and lead to a continuous release of active drug. The enhanced cellular uptake of EDS-TM resulted in significantly higher cytotoxic effect in K562 leukemia cells. Cell cycle analysis further demonstrated the significantly higher G2/M phase arrest of cancer cells. Immunoblot analysis clearly revealed the potential of EDS-TM in inducing apoptosis of cancer cells which could improve the anticancer efficacy in leukemia. Importantly, EDS-M and EDS-TM significantly prolonged the circulation profile of EDS throughout until 24h, indicating the potential of targeted nanoparticulate delivery system. The prolonged blood circulation potential of micellar formulations might improve the therapeutic potential of drug by increasing its bioavailability in the serum. It would be worthwhile evaluating the effects of the EDS-loaded micelles on cancer cells in vivo for clinical application.
Collapse
Affiliation(s)
- Yu Sun
- Nanchang University, The First Clinical Medical College, Nanchang, Jiangxi, 330006, China
| | - Zhong-Liang Sun
- Nanchang University, The First Clinical Medical College, Nanchang, Jiangxi, 330006, China; Department of Hematology, Shandong Jining No. 1 People's Hospital, Shandong, 272011, China.
| |
Collapse
|
7
|
González-Fernández Y, Zalacain M, Imbuluzqueta E, Sierrasesumaga L, Patiño-García A, Blanco-Prieto MJ. Lipid nanoparticles enhance the efficacy of chemotherapy in primary and metastatic human osteosarcoma cells. J Drug Deliv Sci Technol 2015. [DOI: 10.1016/j.jddst.2015.08.004] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Aznar MÁ, Lasa-Saracíbar B, Blanco-Prieto MJ. Edelfosine lipid nanoparticles overcome multidrug resistance in K-562 leukemia cells by a caspase-independent mechanism. Mol Pharm 2014; 11:2650-8. [PMID: 24865362 DOI: 10.1021/mp5000696] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The antitumor ether lipid edelfosine is the prototype of a novel generation of promising anticancer drugs that has been shown to be an effective antitumor agent in numerous malignancies. However, several cancer types display resistance to different antitumoral compounds due to multidrug resistance (MDR). Thus, MDR is a major drawback in anticancer therapy. In that sense, the leukemic cell line K-562 shows resistance to edelfosine. This resistance is overcome by the use of nanotechnology. The present work describes the rate and mechanism of internalization of free and nanoencapsulated edelfosine. The molecular mechanisms underlying cell death are described in the present paper by characterization of several molecules implied in the apoptosic and autophagic pathways (PARP, LC3IIB, caspases-3, -9 and -7), and their pattern of expression is compared with the cell induction in a sensitive cell line HL-60. Results showed different internalization patterns in both cells. Clathrin and lipid raft mediated endocytosis were observable in edelfosine uptake, whereas these mechanism were not visible in the uptake of lipid nanoparticles, which might suffer phagocytosis and macropinocytosis. Both treatments induced caspase-mediated apoptosis in HL-60 cells, whereas this cell death mechanism was unnoticeable in K-562 cells. Moreover, an important increase in autophagic vesicles was visible in K-562 cells. Thus, this mechanism might be implicated in overcoming K-562 resistance with the treatment by lipid nanoparticles.
Collapse
Affiliation(s)
- María Ángela Aznar
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra , C/Irunlarrea 1, E-31080 Pamplona, Spain
| | | | | |
Collapse
|
9
|
Aznar MÁ, Lasa-Saracíbar B, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ. Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int J Pharm 2013; 454:720-6. [DOI: 10.1016/j.ijpharm.2013.04.068] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2013] [Revised: 03/27/2013] [Accepted: 04/15/2013] [Indexed: 02/08/2023]
|